Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County VOWST Coverage Policy | OpenPayer
    Ask Trek AI about this page
    CurrentVentura County Health Care PlanPolicy N/A

    VOWST (Fecal Microbiota Spores, Live-brpk) Coverage Criteria

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage of VOWST for prevention of recurrent Clostridioides difficile infection in eligible adults and applies to providers submitting requests for a single treatment course.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyVOWST (Fecal Microbiota Spores, Live-brpk)
    Policy CodePolicy N/A
    Change TypeDescription and authorization terminology update
    Effective DateNov 7, 2023
    Last ReviewFeb 20, 2026
    Next Review DateN/A
    Key ActionSubmit chart notes, laboratory results, or other clinical information documenting that all approval criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    The policy description and authorization terminology were updated during a prior review without documented changes to the clinical approval criteria.

    ≥18 yearsMinimum member age
    3 episodesRecurrent CDI requirement
    4 capsules × 3 daysMaximum dosing course
    1 courseTreatment course limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    No reauthorization
    Continued therapy

    VOWST Coverage Criteria

    Initial approval: prevention of recurrent CDI

    Covered for initial approval when ALL of the following are met.

    Initial approval criteria

    • Confirmed diagnosis: Diagnosis of CDI is confirmed by documentation of a positive Clostridioides difficile test.
    • Age: Member is 18 years of age or older.≥18 years
    • Recurrent CDI: Member has recurrent CDI, evidenced by at least 2 episodes of CDI recurrence after a primary episode, for a total of 3 episodes.At least 2 recurrences after the primary episode; 3 total episodes
    • Antibacterial treatment: Member has received at least 10 consecutive days of antibiotic therapy for the current CDI, such as vancomycin or fidaxomicin.≥10 consecutive days
    • Controlled current CDI: The current CDI is controlled, with fewer than 3 unformed or loose stools per day for 2 consecutive days; diarrhea is Bristol Stool Scale type 6–7.<3 unformed/loose stools per day for 2 consecutive days
    • Required bowel preparation

      • Bowel-preparation options

        • Magnesium citrate is administered before the first VOWST dose.
        • Renal impairment option: For impaired kidney function, polyethylene glycol electrolyte solution, such as generic GoLYTELY, is administered before the first VOWST dose.
    • No prior microbiota therapy: Member has not previously received VOWST, Rebyota, or a fecal microbiota transplant.No prior exposure
    • Dose limit: Requested dose does not exceed 4 capsules per day for 3 consecutive days.≤4 capsules per day for 3 consecutive days

    VOWST is not indicated for treatment of active Clostridioides difficile infection (CDI). Coverage is limited to prevention of recurrent CDI in eligible adults following antibacterial treatment.

    Coverage is excluded for members who have previously received VOWST, Rebyota, or a prior fecal microbiota transplant.

    Repeat VOWST courses are not medically supported for reauthorization. Reauthorization is not permitted because the efficacy of repeat courses has not been sufficiently established.

    Clinical Coding Requirements

    Controlled current CDI
    Stool frequencyFewer than 3 unformed or loose stools per day
    DurationFor 2 consecutive days
    Stool classificationDiarrhea corresponds to Bristol Stool Scale type 6–7
    Minimum age
    Minimum age≥ 18 years
    Eligibility populationAdults 18 years of age and older
    Approval criterionMember must be at least 18 years old

    Prior Authorization and Submission Guidance

    Prior Authorization

    Initial Authorization Criteria

    Submit an initial authorization request only when all approval criteria for prevention of recurrent Clostridioides difficile infection (CDI) are met. VOWST is for members age 18 and older after antibacterial treatment for recurrent CDI; it is not indicated to treat active CDI.

    • Positive Clostridioides difficile test documenting CDI.
    • Member is age ≥ 18 years.
    • At least 2 CDI recurrences after the primary episode (3 total CDI episodes).
    • At least 10 consecutive days of antibiotic therapy for the current CDI, such as vancomycin or fidaxomicin.
    • Current CDI is controlled: < 3 unformed/loose stools per day for 2 consecutive days (Bristol Stool Scale type 6–7 defines diarrhea).
    • Magnesium citrate, or polyethylene glycol electrolyte solution (for impaired kidney function), is administered before the first VOWST dose.
    • Member has not previously received VOWST, Rebyota™, or a fecal microbiota transplant.
    • Dose is no more than 4 capsules per day for 3 consecutive days. Approval is limited to 3 months for 1 treatment course only.

    Product Background

    VOWST is an oral capsule formulation containing live purified Firmicutes spores manufactured from qualified-donor human fecal material. The donor-derived spores are intended to help restore intestinal microbial balance and colonization resistance against C. difficile, supporting the prevention of recurrent CDI after antibacterial treatment rather than treatment of active infection.

    Clinical Definitions

    Firmicutes
    Bacterial typeGram-positive bacteria
    Class includedSpecies belonging to the Clostridia class
    Families and species includedMembers of the Enterococcaceae and Lactobacillaceae families, and Lactococcus species
    Controlled current CDI
    Stool frequencyFewer than 3 unformed or loose stools per day
    DurationFor 2 consecutive days
    Bristol Stool ScaleDiarrhea corresponds to type 6–7

    Initial Therapy

    Initial therapy

    Initial approval requires ALL of the following criteria for prevention of recurrent CDI.

    Initial therapy criteria

    • Confirmed diagnosis: Diagnosis of CDI is confirmed by documentation of a positive Clostridioides difficile test.
    • Age: Member is 18 years of age or older.≥18 years
    • Recurrent CDI: Member has recurrent CDI as evidenced by at least 2 episodes of CDI recurrence after a primary episode, for a total of 3 episodes.At least 2 recurrences after the primary episode; 3 total episodes

    Continuation Therapy

    Continued therapy

    Continuation therapy is not authorized.

    No reauthorization: Re-authorization is not permitted because the efficacy of repeat courses of VOWST has not been sufficiently established.

    Approval duration is not applicable for continued therapy.

    VOWST Quantity Limits

    VOWST quantity limit
    Maximum quantity4 capsules
    Daily limit4 capsules per day
    AdministrationOral capsules (PO), once daily (QD)
    VOWST course duration
    Course duration3 consecutive days
    Treatment course1 treatment course only
    Regimen4 capsules once daily for 3 consecutive days
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyVOWST (Fecal Microbiota Spores, Live-brpk)
    Policy CodePolicy N/A
    Change TypeDescription and authorization terminology update
    Effective DateNov 7, 2023
    Last ReviewFeb 20, 2026
    Next Review DateN/A
    Key ActionSubmit chart notes, laboratory results, or other clinical information documenting that all approval criteria are met.
    SourceLink
    On This Page
    VOWST Coverage CriteriaClinical Coding RequirementsPrior Authorization and Submission GuidanceProduct BackgroundClinical DefinitionsInitial TherapyContinuation TherapyVOWST Quantity Limits
    Antibacterial treatment duration
    Minimum durationAt least 10 consecutive days
    Therapy typeAntibiotic therapy for the current CDI
    ExamplesVancomycin or fidaxomicin
    Documentation Required

    Required Supporting Documentation

    The provider must submit documentation supporting that the member has met all approval criteria. Include sufficient clinical records with the request for the plan to verify eligibility and medical necessity.

    • Office or other chart notes describing the CDI history, recurrence pattern, current symptoms, treatment, and response.
    • Laboratory results confirming a positive Clostridioides difficile test.
    • Antibiotic treatment records showing at least 10 consecutive days of therapy for the current CDI, including the agent used and treatment dates.
    • Documentation of current stool frequency and consistency for 2 consecutive days.
    • Medication and clinical history showing the prescribed bowel preparation, kidney-function-related choice of preparation, prior microbiota-based therapies, and proposed VOWST regimen.
    Documentation Required

    Clinical Criteria Documentation

    Clinical documentation must establish the facts required for initial prevention therapy and allow verification that VOWST will be given after, rather than as treatment for, active CDI.

    • Confirmed CDI based on a positive test result.
    • A recurrent-disease history consisting of a primary episode plus at least 2 recurrences.
    • Completion of at least 10 consecutive days of antibacterial treatment for the current CDI.
    • Controlled current CDI with fewer than 3 unformed or loose stools daily for 2 consecutive days.
    • Age of at least 18 years.
    • Pre-dose bowel preparation: magnesium citrate, or polyethylene glycol electrolyte solution when kidney function is impaired.
    • No prior VOWST, Rebyota™, or fecal microbiota transplant exposure.
    • Prescriber’s planned dose and schedule: no more than 4 capsules daily for 3 consecutive days.
    Denial Risk

    Clinical Eligibility Deficiencies

    Authorization may be denied when the request does not meet the population or clinical eligibility requirements for VOWST prevention therapy. VOWST is not indicated for treatment of active CDI.

    • Member is younger than 18 years.
    • Request is for treatment of active CDI rather than prevention of recurrence after antibacterial treatment.
    • CDI is not confirmed by a positive Clostridioides difficile test.
    • Fewer than 2 recurrences after the primary CDI episode are documented.
    • At least 10 consecutive days of antibiotic therapy for the current CDI are not documented.
    • Current CDI is not controlled (3 or more unformed/loose stools per day or fewer than 2 consecutive days meeting the control criterion).
    • Required pre-dose bowel preparation is absent or inappropriate for the member’s kidney function.
    • Member has previously received VOWST, Rebyota™, or a fecal microbiota transplant.
    Denial Risk

    Dose and Repeat-Course Limit

    Do not request dosing beyond the approved single treatment course. Re-authorization is not permitted because the efficacy of repeat VOWST courses has not been sufficiently established.

    • Maximum regimen: 4 capsules per day for 3 consecutive days.
    • Approval duration: 3 months for 1 treatment course only.
    • Repeat courses and reauthorization are not permitted.
    • Requests exceeding the dose, duration, or single-course limit may be denied.
  1. Antibacterial treatment: Member has received at least 10 consecutive days of antibiotic therapy for the current CDI, such as vancomycin or fidaxomicin.≥10 consecutive days
  2. Controlled current CDI: The current CDI is controlled, with fewer than 3 unformed or loose stools per day for 2 consecutive days; diarrhea corresponds to Bristol Stool Scale type 6–7.<3 unformed/loose stools per day for 2 consecutive days
  3. Required bowel preparation

    • Bowel-preparation options

      • Magnesium citrate is administered before the first VOWST dose.
      • Renal impairment option: For impaired kidney function, polyethylene glycol electrolyte solution, such as generic GoLYTELY, is administered before the first VOWST dose.
  4. No prior microbiota therapy: Member has not previously received VOWST, Rebyota, or a prior fecal microbiota transplant.No prior exposure
  5. Dose limit: Dose does not exceed 4 capsules per day for 3 consecutive days.≤4 capsules per day for 3 consecutive days